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a  b  s  t  r  a  c  t
After  brieﬂy  reviewing  the  nature  of  DNA  methylation,  its general  role  in cancer and  the tools  available
to  interrogate  it, we  consider  the literature  surrounding  DNA methylation  as  relating  to  prostate  cancer.
Speciﬁc  consideration  is given  to recurrent  alterations.  A  list  of  frequently  reported  genes  is  synthesized
from  17 studies  that have  reported  on  methylation  changes  in malignant  prostate  tissue,  and  we chart  the
timing  of those  changes  in the  diseases  history  through  amalgamation  of several  previously  published
data  sets.eywords:
rostate cancer
pigenetic
ethylation
iomarkers
We  also  review  associations  with  genetic  alterations  and  hormone  signalling,  before  the  practicalities
of  investigating  prostate  cancer  methylation  using  cell  lines  are  assessed.  We  conclude  by outlining  the
interplay  between  DNA  methylation  and  prostate  cancer  metabolism  and  their  regulation  by  androgen
receptor,  with  a speciﬁc  discussion  of  the  mitochondria  and  their  associations  with  DNA  methylation.etabolism
itochondria
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(http://creativecommons.org/licenses/by/4.0/).
ontents
1. Introduction:  why  consider  the epigenome?. .  . . . .  . .  .  . . . . . . .  . . . . . . . . .  . . . . .  . . . . . .  . .  . . . .  . .  .  . . . . . . .  . . . .  .  . . .  . . . .  . . . .  .  . . . . . .  .  .  .  . . .  .  . . . . . .  .  .  . .  . . .  .  . .  . . .  .  .  . .  . .00
1.1.  The  origins  of  prostate  cancer  are  not  obviously  genomic  . . .  . .  .  . . . .  . . .  . . . . .  .  .  . . .  . .  . . .  .  .  . . .  . . .  .  . . . . . .  .  . .  .  . .  .  .  .  . .  . . . .  .  . . . . . .  .  .  .  .  . .  . .  . .  . . .  . . . .  . .  .  00
1.2.  Considerations  for  DNA  methylation  proﬁling  in  prostate  cancer  . .  .  . . . . . .  .  . . . . . .  .  .  . . .  . . . .  . . .  . . . . .  . . . . . .  . . . .  . . .  .  .  . . . .  .  .  .  . .  .  . . . . . . . . .  .  .  . .  . .  .  .  .  .  00
1.3. The  data  used  in this  review  . . .  .  . .  . . . .  .  . . .  .  . .  .  .  . . . . . . .  . . . .  . . .  . .  . . . . .  . . .  . . . . .  .  .  . . .  . . . . .  . . . . . .  .  . . . . . .  .  . . . .  . .  .  . . . . . . .  . . . . . . . . .  .  . . .  .  .  .  . . . . . . .  . . . . . .  . 00
2.  Recurrent  epigenetic  changes  in  prostate  cancer:  markers  and  drivers  of  disease  evolution  . . .  .  . . .  . . . . . . . .  . .  . . . .  .  .  . . . .  . . .  . .  . . . .  .  . . . . .  .  . . .  . .  .  .  . .  .  . .  .  . 00
2.1.  Early  epigenetic  changes  in prostate  carcinogenesis  .  . . . . . . .  . . . . . . .  .  . . .  .  . . . . . . . .  .  .  . . .  .  .  . . . . . .  .  . . . . . . . . . .  . . .  . .  . .  .  . . . . . .  .  . .  . . .  .  . . . . . .  .  . .  .  . .  .  . .  . .  . 00
2.2.  An epigenetic  ‘ﬁeld-effect’  in cancerous  prostates  .  . .  .  . . . .  .  . .  .  . . .  . .  .  . . . . . . .  . . . . . . .  . . . . . . .  . . .  . .  . . .  . .  . . . . . .  . . . . . . .  .  . . . . . . . . .  .  . . .  .  .  . . . . . . .  . .  . . . .  .  . 00
2.3. Underlying  clonal  stability  and ongoing  epigenetic  evolution  in  prostate  tumours  . . .  . . . .  . . . . . . .  .  . . . . . .  .  .  . . .  .  .  . . . .  .  .  . . .  .  . . . . .  .  . . .  . .  . . .  .  .  .  . .  .  . 00
2.4.  DNA  methylation  markers  for  the detection  and stratiﬁcation  of prostate  cancer  . . . . .  .  . . . . . .  .  . . . . . . .  . .  . . . . .  . . .  .  .  . . . . . . . . . . .  . .  .  .  .  .  . . .  . . . .  . .  .  .  00
2.5.  Epigenetic  regulation  of  alternative  promoter  usage  in prostate  cancer  .  . . .  . . . .  . .  .  . .  . . . . .  . . .  . . .  . . .  . .  . .  . . . . . .  .  .  . . .  .  .  .  . . .  .  .  . . . .  . . . . . .  . . . .  .  . .  .  . .  . 00
2.6. Associations  between  epigenetic  and genetic  alterations  in prostate  cancer  .  .  . . .  . .  . . . . . .  . .  .  . . . .  .  . . . .  . . .  . . .  . .  . . .  .  .  . . .  . . . . . .  .  .  . .  .  . .  . . .  . . .  .  . . .  . . 00
2.7.  Epigenetic  changes  impacting  on  hormone  signalling  in  prostate  cancer  .  . . . . . . .  . . .  . . . . . . .  .  . . . . . .  . . . . . . .  .  . . . .  . . . . . . . . . . .  .  .  .  .  . . .  . . .  . . . .  . .  .  .  . . .  00
2.8.  Prostate  cancer  cell  lines  . . .  . . .  .  . . .  . . .  .  .  . .  .  .  . .  .  . . .  .  . . . . . .  .  . . . . . . .  . . . . .  .  . .  . . . . .  . . . .  . . .  . . .  .  . . . . . . .  . . . . .  . .  .  . . . . . . .  . . . .  .  . . . .  .  .  .  . .  .  .  . . . . . . . .  .  .  . .  .  .  . .  .  . 00
3.  Effects  of the metabolic  pool  on DNA  methylation  .  .  . . .  .  . . . .  . . . . . . .  . . . . .  . . .  .  . . . . . . . .  .  . . . . .  . .  .  . . . . . .  .  . . . . . . .  .  . . .  . . . . .  . . . . . . .  .  . . .  .  .  .  . . .  . . . . . .  . . . .  .  .  .  .  . . .  .  00
4. Mitochondrial  methylation  and  prostate  cancer  . .  . . . .  . . .  . . . . .  . .  . . . . .  . .  .  .  . . . . .  .  . .  . . . .  . .  . . . . .  . . .  . . . .  .  . . . . . . .  . . .  . . . . . . .  .  .  . . . .  .  .  . . . . .  .  .  .  .  . .  . . . .  . . . . .  . . . .  . . 00
4.1. Importance  of  mitochondria  in  PCa  . . .  . . .  .  . . .  . . . .  . . . .  . . .  .  . . . . . . . . . . . . . . .  .  . . . . . .  . .  . . .  .  .  . . .  . . . .  .  . . . . . . . . . . .  . . .  . . .  .  . . . .  . .  .  . . .  . . .  .  .  .  . . . .  . . . . . .  . . .  .  . .  00
4.2.  Reciprocal  regulation  of  nuclear  methylation  and  mitochondria  .  . .  . . .  . . . . .  . .  . . .  . . . . .  . . .  . .  . . . . . .  . . . . . . .  . . .  . . . .  .  . . . . . . .  . . .  .  . .  .  . .  . . .  .  . . . .  . . . . . .  . 00
5.  Current  perspectives  and  future  directions  for  the  role  of  epigenomic  changes  in prostate  cancer  . . . .  .  . . .  . .  . . .  . . . . .  .  . . .  . . . . . . . . . . .  .  .  .  .  . .  . .  . .  . . . . . .  . 00Please cite this article in press as: C.E. Massie, et al., The importance
Biochem. Mol. Biol. (2016), http://dx.doi.org/10.1016/j.jsbmb.2016.04
Acknowledgements .  .  .  . . .  . . . .  . . . .  . . .  .  . . .  .  . . .  . . .  .  . . .  .  . . .  .  . . .  .  . . .  . .  .  .  . . .  .  .  . .  . 
Appendix  A.  Supplementary  data  . .  .  . . .  .  .  . .  .  . . .  .  . . .  . . .  .  . . . . . . .  . . . . . . .  .  . .
References  . . .  .  . .  .  . . .  . . . .  . . . .  . . .  .  . . .  . . . . . . .  . . . .  .  . .  .  .  . .  .  . . . . . . .  .  . .  . . . .  .  . .  . . . . .
∗ Corresponding author.
E-mail address: andy.lynch@cruk.cam.ac.uk (A.G. Lynch).
ttp://dx.doi.org/10.1016/j.jsbmb.2016.04.009
960-0760/© 2016 The Authors. Published by Elsevier Ltd. This is an open access article u of DNA methylation in prostate cancer development, J. Steroid
.009
. . . .  . . . . .  . . .  . . . . .  . . .  . . .  . . .  .  . . .  . . . .  .  . . .  . . . . .  . .  . . . .  .  . . . . .  .  . . .  .  .  . . .  . .  . . . . .  .  . . .  .  .00
 .  . . . .  . . . . .  . . . .  .  . . . . . .  .  . . . . . .  .  . . . .  . . .  . . . . .  . . .  .  . . . . . .  .  .  . .  . . . . .  .  . . . .  .  .  .  . . .  .  . .  .  .  00
 . .  . . .  .  . .  . . . . .  . .  . . . .  .  . . .  .  . . . . . . .  . . . . . . .  .  . .  . . . .  .  . . . . . . .  . . . . . .  . .  .  .  .  .  .  . .  .  .  . .  .  . .  .  00
nder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
 ING ModelS
2 mistr
1
1
g
e
g
S
r
s
T
c
t
w
r
c
8
o
g
t
s
p
c
a
t
r
t
D
a
h
y
i
a
a
t
p
d
ﬁ
o
g
p
s
1
c
c
a
a
o
a
m
f
w
[
s
‘
y
u
4
iARTICLEBMB-4702; No. of Pages 15
 C.E. Massie et al. / Journal of Steroid Bioche
. Introduction: why  consider the epigenome?
.1. The origins of prostate cancer are not obviously genomic
Cancer genomics studies have identiﬁed recurrently mutated
enes and mutation hotspots in a number of cancer types. How-
ver, such studies in prostate adenocarcinomas have identiﬁed no
enes recurrently mutated in more than a seventh of cases [1].
tudies of locally advanced and metastatic prostate cancer have
evealed extensive intratumoural clonal heterogeneity [2–6], in
ome cases revealing clones with distinct genomic origins [3,5].
his extensive clonal and spatial heterogeneity creates a signiﬁ-
ant sampling problem for studies that rely on the use of single
umour specimens. In such studies, intratumoural heterogeneity
ill amplify intertumoural heterogeneity, contributing to the low
ecurrence rates of genes affected by point mutations in prostate
ancer [1].
Other mutation types have higher levels of recurrence, e.g.
p deletions (in 40% of cases) and TMPRSS2-ERG fusions (in 50%
f cases) [7,8], suggesting that these may  be early or conver-
ent events in prostate tumourigenesis. However, many prostate
umours have no deﬁnitive genomic driver event [1]. This is con-
istent with the existence of events that precede the ﬁrst somatic
oint mutations and possibly also the acquisition of the ﬁrst
opy number and structural variants. Epigenomic changes are
mong the candidates for early events. Of these, DNA methyla-
ion changes have been widely studied and found to be the most
ecurrent events in both locally advanced and metastatic prostate
umours [9,10].
In prostate cancer, recurrent genome-wide and locus speciﬁc
NA methylation alterations have been known for decades [11,12]
nd these events impact on gene expression potential [12,13]. The
igh recurrence rates of speciﬁc somatic alterations in DNA meth-
lation support a strong selective pressure for these events and
mplicate them in the development of neoplastic phenotypes and
s rate limiting steps in disease evolution [12,13]. Cytosine methyl-
tion is the most widely studied epigenetic marker in cancer due to
he development of quantitative genomics methods that are com-
atible with tissue samples obtained from surgical specimens. To
ate most studies have used prostate cancer cell lines when pro-
ling chromatin structures and histone modiﬁcations [14–16] and
ther variants of cytosine modiﬁcation have only been assessed at a
lobal level in primary prostate cancer tissue [17]. Therefore for the
urposes of this review we will restrict our focus to the wealth of
tudies that have proﬁled cytosine methylation in prostate cancer.
.2. Considerations for DNA methylation proﬁling in prostate
ancer
DNA methylation is a stable, heritable genome modiﬁcation that
an provide insights into a tumour’s origins and evolution. Methyl-
tion proﬁling is aided by the number of well-developed techniques
nd analysis methods available. It is aided also by the requirement
nly for standard preparation of genomic DNA as input, making it
pplicable to routine tumour tissue collections (i.e. in contrast to
ethods that require cross-linked chromatin).
A range of methylation proﬁling methods have been developed,
rom cis-linked, base-pair resolution bisulﬁte sequencing of the
hole genome (WGBS [18]) or GC-base enriched regions (eRRBS
19,20]), to array based averaging of methylation at speciﬁc CpG
ites [21,22], to locus-averaging methods that identify methylation
peaks’ (me-DIP [23,24]) or that may  be a proxy for functional meth-Please cite this article in press as: C.E. Massie, et al., The importance
Biochem. Mol. Biol. (2016), http://dx.doi.org/10.1016/j.jsbmb.2016.04
lation changes (e.g. MBD  pull-down [25,26]). The most widely
sed platform for studies of clinical tissue samples is the Inﬁnium
50k array [21], that continues to be used due to its reproducibil-
ty, well developed analysis methods and consequent potential for PRESS
y & Molecular Biology xxx (2016) xxx–xxx
integration with a wealth of published data from this platform
[27,28].
Sequencing methods provide the highest resolution proﬁles and
cis-linkage information about the status of adjacent CpGs on the
same strand, but have the largest analytical burden. Standard bisul-
ﬁte sequencing methods do not, however, discriminate between
methyl-cytosine (5-mC) and hydroxy-methyl-cytosine (5-hmC),
although these marks are believed to have different functional con-
sequences. To discriminate 5-hmC and 5-mC a two stage analysis is
required comparing the results of bisulﬁte sequencing (for a com-
bined 5-hmC and 5-mC signal) and oxidative bisulﬁte sequencing
(for 5-hmC alone), followed by subtractive analysis. Alternatively,
me-DIP approaches using 5-hmC and 5-mC speciﬁc antibodies can
also discriminate these signals to provide locus-averaged signals.
Future improvements in sequencing yields and sensitivities for sin-
gle molecule sequencing platforms may  provide different insights
into the epigenetic landscape, for example long read technologies
may  allow better phasing of epigenetic states along chromosome
domains. Recent reports suggest that nanopore-based sequencing
technologies may  be able directly to read the 5-mc or 5-hmc mod-
iﬁcations of cytosine [29].
The DNA methylation landscape varies across the genome,
generally showing higher methylation at repeat sequences and
retrotransposons compared to lower methylation at active gene
promoters and CpG-islands [18,30]. High levels of DNA methyla-
tion at gene promoter regions (and around the transcription start
site) correlates with low gene expression [12,18]. Within a gene
locus the methylation proﬁle can vary widely (Fig. 1A), mean-
ing that comparisons between samples (i.e. differential analysis)
must rely on either comparisons of individual CpG sites or by
deﬁning local methylation domains (e.g. differentially methylated
regions, DMRs) [31]. CpG-islands have low DNA methylation vari-
ance in cancer, while adjacent regions (termed CpG-shelves and
CpG-shores; Fig. 1B) tend to show higher variation. Most recently
locally disordered methylation or epipolymorphisms have been
reported [32,33] and linked to evolutionary plasticity in cancer, as
previously suggested for epigenetic variation [33–35].
The selection of samples for cancer genome sequencing is usu-
ally simple because the aim is to identify somatically acquired
changes (e.g. comparing tumour tissue with a germline control
sample – often blood or buccal swabs). However, tissue spe-
ciﬁc methylation proﬁles mean that the most appropriate control
sample for cancer methylome studies is normal tissue from the
same organ. More stringently, one might aim to match the pro-
portions of cell types (e.g. epithelial, stromal, immune) in the
tumour and normal tissue samples. In many cancer types (includ-
ing prostate cancer) a ‘ﬁeld-effect’ change has been observed in the
tumour adjacent normal tissue, consistent with a pre-neoplastic
state. Therefore, depending on the study aims it may  be most
appropriate to compare epigenetic state between tumours, tumour
adjacent normal tissue and age-matched tumour-free normal
tissue.
1.3. The data used in this review
Through this review we will illustrate key points using previ-
ously published data sets. For ease of comparison, and due to their
greater number, we will focus solely on data generated using the
Illumina Inﬁnium HumanMethylation450 BeadChip. For individual
genes, and to relate methylation levels to gene expression we  will
use the ‘TCGA’ prostate adenocarcinoma data [28], interrogated and of DNA methylation in prostate cancer development, J. Steroid
.009
plotted using the TCGA Wanderer interface [36]. For consistency
we use Wanderer’s associations of probes to genes through-
out, although this naturally leads to probes mapping to multiple
genes.
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Fig. 1. (A) Average methylation proﬁles for prostate tumours (n = 340) and normal prostate tissue (n = 49) at the GSTP1 gene locus using the TCGA data set (see Section 1.3).
(B)  Schematic showing the GSTP1 gene locus, indicating the location of the CpG-island, CpG-shore (<2kb from island) and CpG-shelf (2–4kb from island). (C) Correlation
scatter  plot for GSTP1 expression and methylation (using the 450k array probe highlighted in panel-A). (D) Correlation scatter plot for CDKN2A expression and methylation
( s for p
(
d
s
m
c
nusing  the 450k array probe highlighted in panel-E). (E) Average methylation proﬁle
F)  Schematic showing the gene and CPGI features at the CDKN2A locus.
For the second data set, the ‘Tissue’ data set, we amalgamate
ata from several sources [26,27,37–39] to obtain methylationPlease cite this article in press as: C.E. Massie, et al., The importance
Biochem. Mol. Biol. (2016), http://dx.doi.org/10.1016/j.jsbmb.2016.04
tatuses for prostates from men  with no prostate cancer (“Nor-
al”), morphologically normal tissue from men  with prostate
ancer (“Benign”), benign prostatic hyperplasia (“Hyperplasia”),
eoplastic tissue (“Neoplasia”), primary tumours (“Tumour”) androstate at the CDKN2A gene locus using the Prostate TCGA data set (see Section 1.3).
metastases (“Metastasis”). We  also obtain blood proﬁles [39] as an
additional reference. of DNA methylation in prostate cancer development, J. Steroid
.009
For Fig. 3A, where space is a constraint, we  use only a subset
of these drawn from two  sources [26,37]. The third data set, the
‘Cell line’ data set consists of the combined HumanMethylation450
data detailed later in Table 1. Finally, to annotate genes with
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Table 1
Public prostate cell line methylation data (January 2016).
GoldenGate 27k 450k Nimblegen MBD-seq RRBS NOMe-seq MRE-seq MEDIP
DU-145 GSM1125684,
GSM696035
GSM573668 GSM1633638,
GSM1323599
SRX118022, SRX118022,
GSM1050087,
GSM1050090,
GSM1050093,
GSM1050096,
GSM1050099
GSM1050102
PC3  GSM1125685,
GSM696036
GSM573670 GSM1633598,
GSM1519011 to
GSM1519016*,
GSM1323600
GSM1142996 to
GSM1143004
GSM1050088,
GSM1050091,
GSM1050094,
GSM1050097,
GSM1050100
GSM1050103 GSM1383852
LNCaP  GSM1125683,
GSM696034
GSM573669 (FGC) GSM1519017,
GSM1519018,
GSM999368,
GSM847569 to
GSM847571
GSM1142987 to
GSM1142995*
SRX118021, GSM605080,
GSM605081
GSM683768,
GSM683776,
GSM683862,
GSM683863,
GSM683924,
GSM683946
GSM684592,
GSM684597 to
GSM684600
GSM605948,
GSM605950,
GSM605954 to
GSM605956
ARCaP  GSE35246 (27
samples*)
PrEC GSE35246 (4
samples*)
GSM999369,
GSM847572 to
GSM847574
GSM1142978 to
GSM1142986*
GSM605082, GSM605083 GSM683760,
GSM683838
GSM1383851 GSM684593 to
GSM684596
GSM605945 to
GSM605947,
GSM605951 to
GSM605953
PrED  SRX118020
RWPE-1 GSM573671 GSM1323601
Detailing the data available for common prostate cell lines from Gene Express Omnibus (GSM/GSE) and the Short Read Archive (SRX). * – includes control and treated cell lines. Platforms included include Illumina Goldengate
Methylation Cancer Panel I (“GoldenGate”), Illumina Inﬁnium HumanMethylation27 BeadChip (“27k”), Illumina Inﬁnium HumanMethylation450 BeadChip (“450k”), Nimblegen Human DNA Methylation 3x720K CpG Island Plus
RefSeq  promoter array (“Nimblegen”), methyl-CpG binding domain protein-enriched genome sequencing (“MBD-seq”), Reduced representation Bisulﬁte sequencing (“RRBS”), Nucleosome Occupancy and Methylome sequencing
(“NOMe-seq”), Methylation-sensitive Restriction Enzyme Sequencing (“MRE-seq”), and Methylated DNA Immunoprecipitation Sequencing (“MEDIP”).
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ndrogen receptor (AR) regulation data, we use two previously-
ublished androgen-treated cell line time-course data sets [40,39].
. Recurrent epigenetic changes in prostate cancer:
arkers and drivers of disease evolution
Recurrent alterations in DNA methylation at the GSTP1 gene
romoter and concomitant loss of GSTP1 expression in prostate
umours were reported over 20 years ago [12]. This ﬁnding has
een replicated in countless independent studies (for example
9,41,42]) and well over 1000 samples (reviewed in [43]), providing
trong evidence that DNA methylation changes are indeed recur-
ent across patient cohorts and could be useful markers for the
linical detection of prostate cancer [9,44].
Several other genes have also been reported to be recur-
ently hypermethylated in prostate cancer by multiple studies.
ynthesizing data from 17 studies [2,10,20,22,24,26–28,38,45–52],
e identify 861 genes that are reported in two or more stud-
es, 168 in three or more (detailed in Supplementary Table 1
nd Supplementary Fig. 1), and 45 that are reported in four or
ore studies (Fig. 2). Some gene families are also recurrently
ffected, consistent with functional convergence, including multi-
le changes at the HOX gene family loci (Fig. 2 and Supplementary
ig. 1) [10,49].
.1. Early epigenetic changes in prostate carcinogenesis
The high recurrence rates of these DNA methylation changes
uggest that they may  be early events in tumourigenesis. Indeed
everal studies have detected many such methylation changes in
eoplastic samples (PIN) and tumour adjacent, morphologically
enign tissue [53,54,27]. Indeed the majority of loci that have been
uggested as differentiating benign and cancerous prostate appear
lready to have undergone epigenetic changes in neoplastic tissue
Fig. 2) impacting on their potential as prostate cancer markers, but
ighlighting early or shared events in cancer evolution.
Prospective multi-region sampling studies with good clinical
nnotations are therefore needed to map  tumour speciﬁc mark-
rs comprehensively, in order to improve diagnostic accuracy from
issue biopsies and non-invasive monitoring. Given the current
ver-treatment of primary prostate cancer it is also imperative that
obust panels of markers are developed to allow patient stratiﬁca-
ion for active surveillance or clinical intervention.
.2. An epigenetic ‘ﬁeld-effect’ in cancerous prostates
Recent studies suggest that DNA methylation changes in tumour
djacent ‘normal’ tissue may  reﬂect a ‘ﬁeld effect’ in cancerous
rostates [50,24,27]. DNA methylation proﬁles have been reported
o differ between tumour adjacent benign tissue and benign tis-
ue from cancer-free prostates [50,24], while benign samples taken
t different distances from prostate tumours show similar proﬁles,
upporting a wide clonal expansion of morphologically normal cells
50].
This observation is consistent with the outgrowth of tumour
lones originating from clonal benign and PIN tissue, a concept
upported by a recent study comparing multiple benign, neopla-
ia and tumour samples from the same cancerous prostates [27]. In
his study a common phylogenetic ‘trunk’ could be identiﬁed using
ither copy number or DNA methylation proﬁles, linking tumour
amples, PIN and adjacent normal prostate samples. This indicationPlease cite this article in press as: C.E. Massie, et al., The importance
Biochem. Mol. Biol. (2016), http://dx.doi.org/10.1016/j.jsbmb.2016.04
f a shared clonal ancestry contrasts with the more sparse data from
enome sequencing studies, where few point mutations, indels or
tructural variants link separate tumour foci and pre-cancerous
issues [5], suggesting that the expansion of genetically mutated PRESS
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clones is a later event than the expansion of clones harbouring DNA
methylation alterations.
Further studies are required to deﬁne more clearly the early
neoplastic and tumour initiating events and also comprehensively
to distinguish early events from convergent evolution. Longitudi-
nal monitoring through the life-history of a patient with prostate
cancer would be required to give a deﬁnitive answer to these
questions, although this would be very difﬁcult to achieve. An alter-
native approach would be to combine multi-region tissue sampling
cohorts with base-pair resolution methylation sequencing to dis-
tinguish early events from convergent evolution. Understanding
this would impact on the utility of these changes both as markers
of early tumourigenesis and as targets for preventative medicine.
2.3. Underlying clonal stability and ongoing epigenetic evolution
in prostate tumours
GSTP1 methylation is present at all stages of prostate can-
cer development [51], showing that speciﬁc epigenetic changes
can be maintained throughout disease evolution. In addition,
methylome-wide studies have shown stable epigenetic proﬁles
between metastatic deposits within a patient [26] and clear evi-
dence of shared origins for metastatic deposits in primary tumours
and premalignant lesions [27]. Interestingly, in most cases neo-
plastic lesions (PIN) were evolutionarily more similar to localized
tumour samples, whereas metastatic deposits were often more
closely related to a separate subset of localized tumour samples
[27].
Hypomethylation of repeat sequences and cancer testes anti-
gens have been suggested to be relatively late events in prostate
cancer development [55,30]. In addition, metastatic sites have been
reported to show greater divergence for DNA hypomethylation
within some patients [30].
Studies showing clonal stability of DNA hypermethylation, and
evidence of a subset of clones that are more closely related to
metastatic disease, support the idea of using DNA  methylation
markers for prostate cancer detection and prognosis.
2.4. DNA methylation markers for the detection and stratiﬁcation
of prostate cancer
Combined panels of candidate DNA methylation markers have
been shown to have high sensitivity and speciﬁcity for the discrim-
ination of prostate cancers from benign tissue [51,38], with more
recent studies showing proof of principle in prostate biopsy mate-
rial [38]. Several studies have shown the potential for non-invasive
monitoring of DNA methylation in cell-free DNA to detect prostate
cancer [56–59]. Many of these studies show remarkable sensitivity
and support the use of these tests for monitoring disease pro-
gression, however larger studies will be required to determine the
clinical utility of these promising tests for prostate cancer diagnosis.
A molecular stratiﬁcation for prostate cancer was  proposed
recently [28]. This large study found associations between genomic
alterations and epigenetic proﬁles, that may  represent a phenotypic
difference between these molecular subtypes of prostate cancer.
One third of ERG-positive tumours clustered together with a dis-
tinct hypermethylation proﬁle [28]. The one percent of prostate
cancers that harbour mutations in the gene encoding isocitrate
dehydrogenase (IDH1) were found to have a divergent genome-
wide hypermethylation proﬁle [28]. This is likely to be a result of
IDH1-R132H mutations driving production of the oncometabolite
2-hydroxyglutarate (2HG), with a reciprocal decrease in alpha- of DNA methylation in prostate cancer development, J. Steroid
.009
ketoglutarate, a key component in the metabolic pathways of DNA
methylation (the upstream metabolic processes are described in
Section 3). It is currently unclear whether these molecular subtypes
have clinical utility, what other factors impact on the observed
ARTICLE IN PRESSG ModelSBMB-4702; No. of Pages 15
6  C.E. Massie et al. / Journal of Steroid Biochemistry & Molecular Biology xxx (2016) xxx–xxx
−1
−0.9
−0.8
−0.7
−0.6
−0.5
−0.4
−0.3
−0.2
−0.1
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
No
rm
al
Be
nig
n
Be
nig
n 
(TC
GA
)
Hy
pe
rpl
asi
a
Ne
op
las
ia
Tu
m
ou
r
Tu
m
ou
r (T
CG
A)
Me
tas
tas
is
VC
aP
LN
Ca
P
All
 (TC
GA
)
Be
nig
n 
(TC
GA
)
Tu
m
ou
r (T
CG
A)
GeneCorrel ation
Probe
DM Probe
Co
rre
lat
ion
 wi
th
ex
pre
ss
ion
Me
dia
n B
eta
 
m
eth
yla
tio
n
AR
 tim
e s
eri
es
au
toc
or
re
lat
ion
cg10369363 GRASP cg00817367
cg07485916 RHCG cg01837657
cg11603759 PHOX2A cg24530250
cg19513834 POU3F3 cg19513834
cg18459489 VAX1 cg25527090
cg04482110 TMEM106A cg21211480
cg26104932 CYP27A1 cg26104932
cg19456540 SIX6 cg19456540
cg09813610 IRX1 cg10530883
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cg15110353 LBX1 cg12646649
cg19183743 HOXA3 cg16644023
cg13570101 NKX2−5 cg13570101
cg07345734 NKX2−1 cg08315174
cg04676771 BARHL2 cg15979173
cg21932416 HOXD8 cg09238180
cg27175287 FOXE3 cg01281911
cg13473120 LHX2 cg14425564
cg06483432 KIT cg27154163
cg00487187 HHEX cg10299976
cg04149039 EN2 cg23426473
cg25243775 FBLN1 cg08149253
cg18750960 HOXD4 cg18750960
cg03916909 NKX2−2 cg03916909
cg18179931 GP5 cg10398774
cg01830294 WNT2 cg20064455
cg05189570 BDNF cg03167496
cg00517511 TBX3 cg19713038
cg24228707 DLX1 cg07181565
cg22389949 ESR1 cg08161546
cg17606785 EFS cg18844382
cg08857479 HOXC11 cg03132556
cg17227967 LAMP5 cg17227967
cg24842086 TBX15 cg13080379
cg06661450 LHX9 cg13364881
cg22153728 RUNX3 cg11018723
cg15607292 RARB cg24396624
cg22953017 AOX1 cg13875120
cg03234186 ZNF154 cg05661282
cg18536802 APC cg22035501
cg12840719 CDKN2A cg12840719
cg25820279 HOXD3 cg14666564
cg10180406 PTGS2 cg26564040
cg18258224 WT1 cg13641903
cg05244766 GSTP1 cg06928838
Fig. 2. Heatmap summary of genes and marker probes associated with DMRs reported in four or more studies. Left panel, correlations between gene expression (RNA-seq)
and  DNA methylation (450k arrays), from the PRAD TCGA data set (450k probe IDs indicated on the left). Middle panel, average methylation levels (Beta-values) from multiple
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ines  (autocorrelation values denote a change with time following stimulation – a v
ith  a cross where not obvious.
ethylation proﬁles, or what the phenotypic consequences of these
pigenetic differences might be.
More effective diagnosis of prostate cancer would alleviate some
f the current burden on health systems and decrease invasive
rocedures on healthy men. However, it is also critically impor-
ant to distinguish indolent from aggressive prostate cancers so
hat aggressive treatments can be appropriately allocated to those
atients who require such interventions, sparing other patients
nnecessary over-treatment. Associations between DNA methyl-
tion changes and prognosis have been reported, including the
orrelation of PTGS2 (COX-2), HOXD3 and ABHD9 hypermethylation
ith recurrence [51,22].
One study aiming to identify prognostic methylation mark-
rs for prostate cancer highlighted over one hundred candidate
enomic loci [49]. However, the discrimination between relapsed
nd non-relapsed samples was far weaker than between tumour
nd benign samples [49], indicating more subtle differences
etween these groups. Among the candidate prognostic markers
nly PTGS2 (COX-2) was validated from the previously mentioned
tudies. However, other studies have reported more promising
ndings by combining pilot genome-wide screening with targeted
pproaches on large test and validation cohorts [60]. A three gene
ethylation signature (AOX1, C1ORF114,  HAPLN3) was able to pre-
ict biochemical recurrence with respective hazard ratios of 1.9 and
.3 in test and independent validation cohorts [60].
By taking a different approach and examining morphologically
ormal tissue adjacent to tumours, the methylation status of GSTP1
nd APC has been reported to have prognostic utility [61]. GSTP1
nd APC methylation in tumour adjacent tissue correlated with thePlease cite this article in press as: C.E. Massie, et al., The importance
Biochem. Mol. Biol. (2016), http://dx.doi.org/10.1016/j.jsbmb.2016.04
ethylation of these loci in matched tumour samples [61], consis-
ent with either shared clonal ancestry or convergent evolution.
ither hypothesis to explain these DNA methylation changes in
umour adjacent tissue would support a ﬁeld-effect in a subset ofht panel, androgen-stimulated gene expression changes in two prostate cancer cell
f zero indicates no systematic change after stimulation). Missing data are indicated
prostate cancers that may  impact on outcome. These results are
consistent with other reports of an epigenetic ﬁeld effect (sum-
marized in Section 2.2) and conﬁrm other reports that epigenetic
proﬁling could be a useful tool to avoid false-negatives in diagnostic
biopsies [62].
In addition to these important targeted studies in large cohorts
there is a need for methylation proﬁling studies that implement
sensitive, genome-wide methods across samples representing the
full range of prostate cancer disease stages to provide a clearer pic-
ture of the likely diagnostic and prognostic utility of these and other
DNA methylation markers for prostate cancer.
2.5. Epigenetic regulation of alternative promoter usage in
prostate cancer
In addition to gene silencing, DNA methylation can modulate
gene isoform expression by impacting on alternative promoter
regions. For example DNA methylation at the RASSF1,  APC and
NDRG2 loci were shown to result in differential isoform expres-
sion [46]. This isoform selective expression was actively enforced
by the epigenetic status at these loci, as shown by reversal of the
isoform expression proﬁle upon treatment with the demethylat-
ing agent 5-aza-cytidine [46]. Similar events have been reported in
other studies in prostate cancer [63], however the true extent of
this feature will only be made clear by large cohort studies com-
bining comprehensive methylation proﬁling with RNA-sequencing
on the same samples. An exemplar study leveraged the large RNA-
sequencing gene expression data sets generated by TCGA groups
to identify isoform switching in multiple tumour types (includ- of DNA methylation in prostate cancer development, J. Steroid
.009
ing prostate cancer), and speculate that epigenetic factors could be
responsible [64]. In this study, tumour samples could be accurately
identiﬁed solely by isoform switching signatures, highlighting the
potential for isoform switching as a marker for prostate cancer.
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.6. Associations between epigenetic and genetic alterations in
rostate cancer
Given the early and recurrent acquisition of GSTP1 hypermeth-
lation in prostate tumourigenesis many studies have suggested a
ole for GSTP1 silencing in driving disease evolution by increasing
he mutation rate [65–68]. Recent studies integrating methylation
roﬁling with genome sequencing have uncovered additional asso-
iations between the epigenetic and genetic changes in prostate
ancer.
Firstly, it has been shown that the methylation levels in matched
enign samples are increased at mutated CpG sites in the tumour
n comparison to non-mutated CpGs. [20]. This is consistent with
he hypothesis that methylated cytosines are deaminated to uricil
and subsequently copied as thymine), a process believed to drive
he observed high C-to-T mutation rates observed in prostate and
ther cancer types [69,5].
More surprisingly, it has been reported that sites of tandem
uplication events in prostate cancer are frequently hypomethy-
ated, while interchromosomal translocation break points are
requently hypermethylated [20]. These intriguing observations
ill need to be investigated in larger cohorts with paired methy-
ome sequencing and genome sequencing to better characterize
hese associations.
Several studies have also suggested a link between ETS gene
usion status and DNA methylation proﬁles [46,45,48,28]. LINE
epeats show differential methylation between ERG-positive and
RG-negative prostate tumours [46], differentially methylated
egions associated with ERG status have been identiﬁed [48] and
lternative mechanisms for EZH2 activation have been proposed in
RG-negative tumours to phenocopy at least some of the conse-
uences of ETS gene fusions [45]. The implications of molecular
ubtype differences in DNA methylation proﬁles are signiﬁcant.
ifferences between ETS-fusion positive and negative cases high-
ight the interplay between epigeneic state, gene rearrangements
nd hormone signalling, since the AR regulates ETS-fusions and AR
ignalling is altered in ETS-positive tumours [15]. Equally, these
ffects could lead to misinterpretation of studies that cannot take
hem into account.
.7. Epigenetic changes impacting on hormone signalling in
rostate cancer
In addition to interactions with genomic events, the epigenetic
roﬁle has been linked to AR signalling, both as a modulator of
ormone response and a driver event in progression to Castra-
ion Resistant Prostate Cancer (CRPC). AR-bound enhancers were
bserved to show greater intratumoural DNA methylation varia-
ion than other enhancer sites [27], suggesting clonal plasticity in
he AR regulome.
An integrative analysis of copy number and DNA methylation
n CRPC revealed convergence on the androgen synthesis path-
ay, with copy number and methylation changes converging on
SD17B2 and other targets that may  be involved in hormone ther-
py resistance [10].
Loss of AR protein expression is a characteristic of hormone-
elapsed prostate cancer (PCa) that is no longer dependant on AR
ignalling, a phenotype that is becoming more common following
he clinical use of second generation AR targeting therapies [70,71].
pigenetic silencing of AR gene expression has been reported in
rostate tumour samples [72,73] and treatment of AR negative PCaPlease cite this article in press as: C.E. Massie, et al., The importance
Biochem. Mol. Biol. (2016), http://dx.doi.org/10.1016/j.jsbmb.2016.04
ells with the global demethylating agent 5-aza-deoxycytadine can
nduce functional AR signalling in these cells [73–76]. However,
ther studies in CRPC have reported no change in AR promoter
ethylation [10], suggesting either differences between analysis PRESS
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methods or possibly patient cohorts treated with different hor-
mone therapies.
Combining androgen signalling blockade with the demethy-
lating agent 5-aza-deoxycytadine increased response in the
preclinical models of PCa [77,75], suggesting that future studies
combining demethylating agents with second generation AR block-
ade may  improve patient outcome or delay relapse by targeting the
AR, its target genes or upstream pathways.
Oestrogen receptor alpha and beta methylation have also been
identiﬁed in some studies of prostate cancer samples [78,51,46,26].
Although these methylation changes at ER genes are not high-
lighted in the majority of studies it is noteworthy that studies
reporting ER gene methylation used MSP  [51], MBD-pulldown [26]
or restriction enzyme based methods [46] (consistent with either
limitations of the more commonly used 450k arrays at these loci
or convergent artefacts between the other methods). Future stud-
ies should aim to assay DNA methylation at the ERS1 and ESR2
loci in prostate tissues to determine whether this could affect
the interplay between nuclear hormone receptors and be another
mechanism through which epigenetic changes impact on hormone
signalling in prostate cancer.
A large number of these putative epigenetic markers were iden-
tiﬁed by methylation proﬁling of prostate cancer cell lines. In
addition these cell line models are the most widely used tools
for functional validation studies of candidate gene silencing or de-
repression events identiﬁed from genome-wide proﬁling studies.
Therefore we  summarize the utility and limitations of these models
below.
2.8. Prostate cancer cell lines
It has for some time been recognized that immortalized cell
lines do not, in respect of their methylation patterns, reﬂect the
cells from which they originate; typically immortalized cells exhibit
hypermethylation of CpG islands [79–81] although it has been
noted that this may  represent selection pressure where highly
methylated cells are more likely to be immortalized successfully
[82] and there are suggestions that the methylation changes can
predate immortalization [83].
The characteristic methylation changes that occur in immortal-
ized cells are similar to the changes seen in cancers [84,85] raising
the hope that the epigenetics of cancer cell lines may  represent
malignant tissue well. Recent reports argue that it is speciﬁcally the
immortalization of cells rather than other oncogenic activity that
leads to changes in methylation proﬁle [86]. Intriguingly, sites that
are methylated in cancer cell lines are enriched for NANOG binding
sites [87]. As well as its role in maintaining stem cell pluripotency,
NANOG has been shown to be pro-tumourigenic in prostate cancer
cell lines, conferring cancer-stem-cell-like properties [88], and is
directly androgen regulated [89].
Early targeted studies identiﬁed good agreement between
primary cancers and cell lines [90,91], but broader differences
may  mean that only a minority of tumours are well-represented
by cell lines. Genome-wide proﬁling has revealed xenografts to
be a better model in head-and-neck squamous cell carcinomas
[92], while a recent paper has reported near-complete loss of 5-
hydroxymethylcytosine [93] – raising questions about cell lines’
value in this regard.
The utility of prostate cell lines is further affected by the fact
that the commonly used prostate cancer cell line models (recently
reviewed elsewhere [94]) were derived from metastases, and of DNA methylation in prostate cancer development, J. Steroid
.009
metastasis itself is associated with changes in methylation proﬁles
[95,96]. Nevertheless, substantial public data exist for a number of
prostate cell lines as denoted in Table 1, notably LNCaP, PC3 DU-145
and PrEC, making them an attractive resource.
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Fig. 3. Cell lines as a representation of primary tumours. (A) Clustering of our exam-
ple  cell line and tissue data sets (described in Section 1.3). The distance between
two samples is deﬁned as Cohen’s Kappa measure of agreement (applied after
dichotomizing methylation beta values). (B) Illustrating, from the cell line and tissue
data sets, the median proportion of methylation at loci near the GSTP1 promoter. As
expected, the cancer cell lines are generally hypermethylated in this region, as are
the neoplastic and malignant tissues. (C) Illustrating, from the cell line and tissue
data  sets, the median proportion of methylation at loci near the TERT gene. An area
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[107–110]. Of the polyamines normally produced by the prostaten  the gene promoter shows progressively increased methylation levels, with the
ancer cell lines’ levels most in keeping with metastases.
In Fig. 3A, we cluster the available Illumina Inﬁnium Human-
ethylation450 BeadChip cell line data with our example Tissue
ata set. It is notable that inter-sample heterogeneity increases
s one progresses through normal, benign, tumour and metasta-
is samples. Reﬂecting their origins, the prostate cancer cell lines
re more alike the metastasis samples than they are the primary
umour samples, while the PrEC cells cluster with the normal sam-
les.
It should be noted that all of the cell lines show levels of agree-
ent with primary tumours that are substantially above chance,
nd that their greater similarity to metastases only requires carePlease cite this article in press as: C.E. Massie, et al., The importance
Biochem. Mol. Biol. (2016), http://dx.doi.org/10.1016/j.jsbmb.2016.04
o be taken over the interpretation of any results arising. The cell
ines still reﬂect the behaviour of primary tumours at key loci such
s GSTP1 (Fig. 3B), although at loci such as the promoter of TERT PRESS
y & Molecular Biology xxx (2016) xxx–xxx
there appears to be progressively greater DNA  methylation as one
moves from normal tissue, through hyperplastic and neoplastic tis-
sues to primary tumours and metastases, the malignant cell lines
showing greater values still (Fig. 3C).
Despite the inevitable caveats about the use of cell lines,
they offer natural advantages for the inference of function. They
enable one to run controlled experiments with identical subjects in
each/every arm, and make it possible to measure multiple charac-
teristics (e.g. genome-wide methylation and transcript abundance)
on effectively the same samples. Both of these have been exploited
to address questions of prostate cancer biology.
To understand better the methylation-driven regulation of the
cancer genome, mRNA expression data are the natural orthogonal
data to bring into an integrative analysis. In this manner, the
methylation-regulated nature of key genes and alternative trans-
criptional start site usage have been explored in prostate cancer
[46,97].
A substantial body of work has linked DNA methylation with
other epigenetic marks better to understand gene regulation in
(prostate) cancer. The H3K27me3 mark at promoters is associated
with inactivated genes, while methylation of promoters is similarly
associated with gene repression, but the two mechanisms have
been seen to be neither exclusive nor deterministically linked in
LNCaP [98]. Where the two  mechanisms do coexist, a dual ther-
apy to reinstate expression of tumour suppressor genes becomes a
possibility [99]. Elsewhere it has been shown that a genome-wide
restructuring of nucleosome densities is associated with changes
in DNA methylation of enhancer regions of PCa cell lines [100].
Other studies have sought to explain epigenetic mechanisms
of treatment and resistance to treatment. Epigenetic silencing of
SLFN11 has been associated with resistance to platinum-based
chemotherapies in a number of cell lines including DU-145 and
PC3 [101], an epigenetic mechanism of the preventative agents sul-
foraphane and 3,39-diindolylmethane is elucidated [102], and the
mechanism of Genistein has been shown not to be dependent on
broad methylation changes, but rather histone acetylation [103].
Perhaps most interestingly for our topic, a recent report has
shown that dosing cells with S-adenosylmethionine (SAM) inhibits
invasion [104]; the same group having previously identiﬁed a role
for hypomethylation in the metastasis of prostate cancer [105].
SAM is an important methyl donor for histone, DNA and RNA
methylation, and all general protein lysine and arginine meth-
ylation (as described in Section 3). The demonstration, in vitro
and in vivo, that replenishing the reservoir of methyl donors
can inhibit metastasis (while only increasing the methylation
status of speciﬁc loci rather than reversing the genome-wide
hypomethylation) provides some evidence of a mechanistic role
for the methylation patterns in metastases, highlights the impor-
tance of the available metabolic pool for cancer progression, and
invites consideration of the broader role of SAM in the metabolic
pathways.
3. Effects of the metabolic pool on DNA methylation
The prostate gland is a metabolically specialized organ
responsible for supporting sperm viability. This specialization
is characterized by net secretion of citrate into the seminal
ﬂuid [106]. Whilst a signiﬁcant reduction in the production
of these metabolites has been reported in numerous mag-
netic resonance spectroscopy studies on clinical samples, the
molecular drivers for this down-regulation remain controversial of DNA methylation in prostate cancer development, J. Steroid
.009
gland, spermine is particularly abundant [111]. Rat models of
castration-induced regression and testosterone-induced regrowth
of the prostate gland have shown that polyamine production is
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Fig. 4. Schematic representation of metabolic pathways that impact on DNA methylation in prostate cancer. The core DNA methylation pathway is represented at the top of
the  schematic, with connected pathways of relevance to prostate cancer shown below. Colour key relates to metadata annotations shown in Fig. 5. Values for each metabolic
s eps ar
> .2; th
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a
5
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ptep  are compressed into a single summary to simplify the schematic. Metabolic st
0.5;  there is a mean methylation change between tumour and normal tissue of ±0
etails).
ightly regulated by androgens, in part through control over the
xpression of key biosynthetic enzymes (ornithinedecarboxy-
ase (ODC), S-adenosylmethionine decarboxylase (AMD1)
nd spermidine synthase (SMS); highlighted in Figs. 4 and
) [112–114]. The methyl donor in this pathway is S-
denosylmethioninamine (decarboxy-AdoMet), a metabolite
hat is directly downstream of the DNA methylation donor S-
denosylmethionine (SAM, AdoMet). Therefore, alterations inPlease cite this article in press as: C.E. Massie, et al., The importance
Biochem. Mol. Biol. (2016), http://dx.doi.org/10.1016/j.jsbmb.2016.04
he ﬂux through either polyamine metabolism or DNA meth-
lation would be expected to affect the available pools of
ethyl-donors, with reciprocal effects on the ﬂux of the other
athway.e annotated if: androgen regulation in LNCaP or VCaP gives autocorrelation values
e correlation of methylation and expression changes is >0.3 or <−0.3 (see Fig. 5 for
The prostate has one of the highest concentrations of
polyamines of any tissue in the body and the expression of these
enzymes is associated with glandular epithelial cells with sig-
niﬁcant quantities of polyamines secreted into seminal ﬂuids.
Spermine levels in clinical samples have been reported to corre-
late positively with the differentiation status of the tumour and in
preclinical models to promote growth inhibition [115,116].
Polyamine synthesis requires one-carbon metabolism and in of DNA methylation in prostate cancer development, J. Steroid
.009
particular methionine metabolism with S-adenosylmethionine
(SAM) which upon decarboxylation acts as the primary amino-
propyl donor for polyamine synthesis (Fig. 4) [117]. Consequently
the fate of methionine and its derivatives may  be inﬂuenced by
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Fig. 5. Heatmap summary of genes in metabolic pathways that impact on DNA methylation (relating to Fig. 4). Left panel, correlations between gene expression (RNA-seq)
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Snd  DNA methylation (450k arrays), from the PRAD TCGA data set (450k probe IDs in
tudies spanning a range of prostate tissue types (450k probes indicated on the righ
ines  (autocorrelation values denote a change with time following stimulation).
hanges in the specialized secretory functions of the prostate gland
s cancer emerges, in particular a decline in polyamine biosynthe-
is and secretion may  enhance the pool of SAM available to support
pigenetic modiﬁcations (metabolic pathway links shown in Fig. 4).
roving causative associations between rates of polyamine biosyn-
hesis and regulation of the epigenetic state via the availability
f SAM is extremely challenging, since methylation patterns can
e highly locus and cell-type dependent and are supported by a
omplex regulatory network downstream of metabolite consump-
ion and upstream of DNA substrates. Furthermore, one-carbon
etabolism consists of a number of additional interconnected
etabolic processes that may  impinge on polyamines and the
pigenome (folate cycle, methionine cycle and glycine/serine
etabolism, Fig. 4).
Prostate cancer is characterized by the activity of transcription
actors, particularly AR but also others such as c-Myc. A natu-
al question then is how the transcription factors and important
nzymes interact with the metabolome and epigenetic status of
 tumour. As indicated earlier, the synthesis of polyamines and
he expression of the key enzymes required for this and a num-
er of other metabolic processes upstream of SAM production arePlease cite this article in press as: C.E. Massie, et al., The importance
Biochem. Mol. Biol. (2016), http://dx.doi.org/10.1016/j.jsbmb.2016.04
riven by AR and associated with differentiated prostate cancers
Figs. 4 and 5). Glycine N-methyltransferase (GNMT) is an enzyme
hich converts glycine to sarcosine and in the process converts
AM to S-adenosylhomocysteine (Fig. 4). In cell-lines expression ofd on the left). Middle panel, average methylation levels (Beta-values) from multiple
ht panel, androgen-stimulated gene expression changes in two prostate cancer cell
the GNMT enzyme is androgen dependent and in tissue samples it
has been shown to be over-expressed in prostate cancers (Figs. 4
and 5) [118,40]. Sarcosine, the product of the reaction catalysed by
GNMT, has also been reported to be elevated and detectable in urine
samples and some studies have associated this with the emergence
of castrate-resistant disease [119,120]. Of the enzymes involved
in one-carbon metabolism GNMT is therefore currently the most
extensively characterized androgen-dependent component of the
pathway. By contrast the expression of enzymes required for ser-
ine metabolism appears in prostate cancer cell-lines to be repressed
by androgens and in other cancer models to be induced by c-Myc
[40,121]. Whilst serine metabolism also impacts on the methionine
cycle, the most direct impact of serine consumption appears to be to
sustain de novo nucleotide biosynthesis in support of elevated rates
of DNA replication and/or transcription and cell proliferation [122].
This in turn is often a feature of cell cycle dysregulation, character-
istic of late-stage, metastatic prostate cancer [123]. Hypothetically
a phasic transition in one-carbon metabolism may  therefore consist
initially of reduced rates of polyamine biosynthesis and enhanced
DNA and histone methylation in localized disease transitioning into
enhanced serine metabolism during metastatic progression. This of DNA methylation in prostate cancer development, J. Steroid
.009
would at least be consistent with the observations that DNA hyper-
methylation is an earlier event in prostate tumourigenesis, while
hypomethylation may  occur in later stage disease (as described in
Section 2).
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The DNA methylation status of a subset of genes encoding these
etabolic enzymes increases between normal samples compared
o benign, tumour and metastasis, consistent with early hyper-
ethylation changes (Fig. 5). A separate set of enzyme-encoding
enes show hypomethylation in metastatic samples compared to
ocalized and pre-malignant samples (Fig. 5), again consistent with
enome-wide observations of later stage hypomethylation (Sec-
ion 2). It is of interest that there appears to be exclusivity of
egulation within the metabolism-related genes illustrated here
Fig. 5), with AR-regulated genes showing little evidence of dif-
erential methylation, and the strongest differentially methylated
enes not being AR-regulated. This despite the independence of the
ata sets from which these characteristics were identiﬁed.
In addition to the potential inﬂuence of upstream enzyme
xpression and metabolite pools on DNA methylation, the de-
ethylation pathway is intricately linked to central metabolism.
he TCA cycle metabolite alpha-ketoglutarate is required for TET
nzyme activity, the ﬁrst step in cytosine demethylation (Fig. 4).
herefore, mitochondrial function may  have a profound effect on
oth cytosine methylation and the levels of hydroxymethylation in
he genome of a cell.
. Mitochondrial methylation and prostate cancer
.1. Importance of mitochondria in PCa
While of general interest in cancer (reviewed, for example by
allace [124]), mitochondria are of speciﬁc interest in prostate
ancer beyond the characteristic zinc-inhibition of TCA cycle and AR
egulation of certain metabolites described in the previous section.
ecent ‘pan-cancer’ analyses have identiﬁed many mutations in
itochondrial DNA, without showing them to be drivers [125,126],
ut animal models have demonstrated the functional impact of
itochondrial genetic mutations on prostate cancer [127] and a
ohort study in humans has identiﬁed associations with prolifera-
ion [3].
The case for DNA methylation changes in the prostate cancer
itochondria themselves is not as clear cut as that for genetic
hanges. Methylation of mitochondrial DNA has been controver-
ial since it was ﬁrst reported [128]. Subsequent papers variously
onﬁrmed this result [129] or reported no such methylation [130].
he discussion has continued since with arguments for and against
ased on sequence analysis [131,132], and use of methylation sen-Please cite this article in press as: C.E. Massie, et al., The importance
Biochem. Mol. Biol. (2016), http://dx.doi.org/10.1016/j.jsbmb.2016.04
itive and insensitive restriction enzymes [133,134]. One aspect of
he argument against the existence of methylation in the mitochon-
ria has been the absence of the actors that facilitate methylation of
uclear DNA. However, recent years have seen the identiﬁcation of
ig. 6. (A) Reprod. Fig. 4 of Chinnery et al. for a high-cellularity prostate cancer sample. P
f  transcription start sites (TSS) were divided between genes listed in MitoCarta and those
cross probes that show most variation in our data. PRESS
y & Molecular Biology xxx (2016) xxx–xxx 11
methyl donors [135], methyltransferases [136,137], and even TET1
present in the mitochondria [138]. This latter observation suppor-
ting reports of 5-hydroxymethylcytosine in the mitochondrial DNA
[136,139]. The history of this topic is reviewed more thoroughly
elsewhere [140].
Recently there have been studies that provide stronger evidence
that epigenetic modiﬁcations of mitochondrial DNA  do indeed
take place. For example, one study identiﬁed methylated bases in
nucleus-free platelets [141], while another used orthogonal and
complementary technologies to proﬁle the mitochondrial methyl-
ation in a wide range of tissue and cell types [142]. Given the unique
behaviour of mitochondria in prostate cancer, if mitochondrial DNA
can be methylated, this is an aspect that may  reward investigation.
4.2. Reciprocal regulation of nuclear methylation and
mitochondria
Apart from direct epigenetic changes to the mtDNA, the
mitochondria have a complex relationship with epigenetic alter-
ations to the nuclear DNA. Of the order of a thousand coding
genes have products that are active in the mitochondria, and
only 13 originate from the mitochondrial DNA. It follows that
any epigenetic regulation of the remaining mitochondrial actors
in the nucleus will likely inﬂuence mitochondrial behaviour. One
study identiﬁed tissue-speciﬁc differentially methylated regions in
mitochondrial-acting nuclear-encoded genes [143] while another
has concluded that epigenetic regulation of mitochondrial-acting
nuclear-encoded genes was higher than other nuclear-encoded
genes [144]. This latter result can be replicated in prostate cancer
using a single tumour sample (Fig. 6A). While this is representa-
tive of the other samples in our example set, with >5000 probes
from regions around the transcription start sites of mitochondrial
actors showing consistent hypomethylation and approximately
400 showing consistent hypermethylation, there is also evidence of
changes in the regulation of these regions with the progression of
disease. Fig. 6B shows a heatmap of the 114 most variable probes
in these regions, and it is apparent that again there are clusters
of probes that variously gain methylation in neoplastic tissue and
continue to do so in tumour and metastases, others with the oppo-
site pattern, and smaller numbers where the changes are primarily
deﬁned by the metastases samples.
DNA polymerase gamma  is responsible for the replication of
mitochondrial DNA and is regulated by the methylation of the POLG of DNA methylation in prostate cancer development, J. Steroid
.009
gene [145,146] leading to associations between mtDNA copy num-
ber and POLG methylation levels. Methylation of the PPARGC1A
gene has also been seen to correlate negatively with mtDNA copy
number.
robes on the Inﬁnium HumanMethylation450 BeadChip that lay within 1000 bases
 that are not. (B) A heatmap of median beta methylation values for different tissues
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While the methylation of some genes can regulate mtDNA copy
umber, it has also been shown that mtDNA copy number can reg-
late some nuclear genes [144,147]. Furthermore, studies using
ybrids have shown that the mitochondria can affect nuclear meth-
lation patterns [139,148]. Given the importance of epigenetics
o prostate cancer regulation, and the characteristic behaviour
f mitochondria (and broader metabolic pathways) in the dis-
ase, these associations demand attention in attempts to unravel
rostate cancer biology.
. Current perspectives and future directions for the role of
pigenomic changes in prostate cancer
It is clear that clonal expansions of cells with stable epigenomic
hanges occur in prostate cancer. DNA methylation changes are
he most recurrent events so far identiﬁed in prostate cancer, and
peciﬁc changes may  associate with outcome. The epigenome con-
inues to evolve throughout the life history of prostate cancer, with
istinct features presenting at different stages and interacting with
peciﬁc genomic changes. It will be crucial to overlay other epi-
enetic changes within the same cohorts of samples to build up a
icture of the epigenetic landscape in prostate cancer. Future stud-
es are also needed to integrate both genomic and epigenomic data
n large cohorts of samples, to elucidate the interaction between
enomic and epigenetic changes, to provide a more comprehensive
iew of the pathways affected in each prostate tumour sample, and
o assess clinical associations with speciﬁc sets of changes.
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